Source: Eur Respir J, 49 (6) 1602168; 10.1183/13993003.02168-2016
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Natalie Terzikhan, Daniel Bos, Lies Lahousse, Lennard Wolff, Katia M.C. Verhamme, Maarten J.G. Leening, Janine F. Felix, Henning Gall, Hossein A. Ghofrani, Oscar H. Franco, M. Arfan Ikram, Bruno H. Stricker, Aad van der Lugt, Guy Brusselle. Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. Eur Respir J, 49 (6) 1602168; 10.1183/13993003.02168-2016

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary artery to aorta ratio and mortality risk in the general population: The Rotterdam study Source: International Congress 2016 – Imaging of COPD and airways: structural and functional assessments Year: 2016 Asthma increases pulmonary thromboembolism risk: a nationwide population cohort study Source: Eur Respir J 2014; 43: 801-807 Year: 2014 The risk of development of coronary artery disease and 10 years Systemic Coronary Risk Evaluation at patients with COPD Source: Annual Congress 2010 - COPD: cardiovascular comorbidities Year: 2010 Pulmonary artery enlargement and mortality risk in moderate to severe COPD: results from COPDGene Source: Eur Respir J, 55 (2) 1901812; 10.1183/13993003.01812-2019 Year: 2020 In Rotterdam, size really does matter: implications of pulmonary artery enlargement on mortality Source: Eur Respir J, 49 (6) 1700750; 10.1183/13993003.00750-2017 Year: 2017 Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model Source: Eur Respir J, 50 (2) 1700740; 10.1183/13993003.00740-2017 Year: 2017 COPD phenotypes and 5-years mortality risk prediction: PALOMB Cohort Source: Virtual Congress 2020 – Comorbidities/multimorbidites and mortality in patients with chronic lung diseases Year: 2020 Coronary artery calcification in COPD is associated with adverse functional assessments and mortality Source: Annual Congress 2012 - COPD is not a pulmonary disease alone Year: 2012 Risk factors for all-cause mortality in patients with COPD: results from the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Pulmonary function is associated with pulmonary artery systolic pressure in the general population: The Rotterdam study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Forced vital capacity paired with Framingham Risk Score for prediction of all-cause mortality Source: Eur Respir J 2010; 36: 1002-1006 Year: 2010 Variation in mortality from pulmonary hypertension by aetiology Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Late Breaking Abstract - Chronic coronary artery disease and decline of lung function as predictors of mortality and exacerbation risk in stable COPD: Results from COSYCONET Source: Virtual Congress 2021 – Lung function evaluation and assessment of airway diseases Year: 2021 Impact of chronic obstructive pulmonary disease on specific-cause of mortality: a national cohort study Source: International Congress 2019 – Lung function evaluation and prognosis of airway diseases Year: 2019 Cause-specific mortality rates in patients with COPD in primary care: a prospective analysis of the Birmingham COPD Cohort Study Source: Virtual Congress 2020 – Epidemiology and understanding of airways diseases in primary care Year: 2020 Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001–2013 Source: Eur Respir J, 51 (1) 1701603; 10.1183/13993003.01603-2017 Year: 2018 Modifiable risk factors for all-cause hospitalization in obstructive lung disease Source: International Congress 2015 – Risk factors and co-morbidities in asthma and COPD Year: 2015 Assessment of cardiovascular comorbidity Source: Eur Respir Mon 2013; 59: 28-49 Year: 2013 COPD and risk of venous thromboembolism and mortality in a general population Source: Eur Respir J 2016; 47: 473-481 Year: 2016